Trial Profile
A Dose Ranging, Parallel Group, Active (Spiriva® Respimat®) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 18 Sep 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
- 11 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2017.